CTX-8371
Undisclosed Oncology Indications
PreclinicalActive
Key Facts
About Compass Therapeutics
Compass Therapeutics is a public, clinical-stage biotech focused on developing sophisticated antibody-based immunotherapies for cancer. The company's strategy centers on leveraging its proprietary technology platforms to rapidly generate diverse therapeutic candidates designed to modulate the tumor microenvironment and coordinate a comprehensive immune attack. With a market cap of approximately $930M, Compass is advancing a pipeline of novel agents, with its lead candidate, tovecimig, in clinical development, aiming to address significant unmet needs in oncology.
View full company profileTherapeutic Areas
Other Undisclosed Oncology Indications Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology Programs | Terns Pharmaceuticals | Preclinical / Early Clinical |